Early access
Sign in
Taking people in SpainPhase 1

Testing Mosunetuzumab with Pirtobrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Tests two drugs together in adults with returning or resistant chronic lymphocytic leukemia.

Key facts

Who runs it
F. Hoffmann-La Roche AG
Where
Barcelona, Madrid, and Pamplona, SpainSee the 3 sitesAlso in 2 other countries, 5 sites
Registry title
A Study to Test How Safe, Effective and How the Body Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status
Recruiting
Phase
Phase 1
People taking part
22 people, planned
Started
6 Oct 2025
Expected to end
29 Jun 2029
Type of study
Interventional
Record updated
13 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) came back or did not respond to earlier treatment. It tests mosunetuzumab together with pirtobrutinib.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Chronic lymphocytic leukemia or small lymphocytic lymphoma that came back (relapsed) or did not respond (refractory) to treatment.

Where in Spain

Also in 2 other countries, 5 sites

  • Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
  • Clinica Universidad de NavarraMadrid, SpainTaking people
  • Clínica Universidad de navarraPamplona, SpainTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Testing Mosunetuzumab with Pirtobrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
13 July 2026